Stroke Trials Registry

Streptokinase
Streptase® Kabikinase®

Action
Thrombolytic agent

Status
US FDA approved for: acute evolving transmural myocardial infarction, pulmonary embolism, deep vein thrombosis, arterial thrombosis or embolism, occlusion of arteriovenous cannulae. In stroke clinical trials, intravenous streptokinase increased stroke mortality or morbidity in several studies. No further development in stroke.

Trial(s)
= Ongoing
= Completed

ASK Australian Streptokinase Trial

MAST-E Multicenter Acute Stroke Trial-Europe

MAST-I Multicentre Acute Stroke Trial-Italy

Web Links and Publications

Thrombolytic Agents, Systemic Patient Information (MEDLINEplus).

Overview of Cochrane thrombolysis meta-analysis.
Neurology. 2001;57(5 Suppl 2):S69-76. Review.

Baseline blood pressure but not early computed tomography changes predicts major hemorrhage after streptokinase in acute ischemic stroke
Stroke 2002 Sep;33(9):2236-42

The influence of baseline prognostic variables on outcome after thrombolysis. MAST-Italy Collaborative Group.
: J Neurol 1999 Nov;246(11):1059-62

Streptokinase in acute stroke: effect on reperfusion and recanalization. Australian Streptokinase Trial Study Group.
Neurology 1998 Mar;50(3):626-32

Risk of aspirin use plus thrombolysis after acute ischaemic stroke: a further MAST-I analysis. MAST-I Collaborative Group. Multicentre Acute Stroke Trial--Italy.
Lancet 1998 Sep 12;352(9131):880

Dissent: an alternative interpretation of MAST-I. Multicentre Acute Stroke Trial--Italy Group.
Lancet 1995 Dec 9;346(8989):1515

UID: 36